.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,321,128

« Back to Dashboard

Details for Patent: 5,321,128

Title: Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
Abstract:This invention relates a method for topical treatment of glaucoma or ocular hypertension by administration of an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure. The invention further relates to compositions comprising said prostaglandin derivatives in an ophthalmologically compatible carrier.
Inventor(s): Stjernschantz; Johan W. (Uppsala, SE), Resul; Bahram (Uppsala, SE)
Assignee: Kabi Pharmacia AB (Uppsala, SE)
Filing Date:Dec 08, 1992
Application Number:07/988,389
Claims:1. A therapeutic composition for topical treatment of ocular hypertension or glaucoma comprising therapeutically effective amount of a PGF.sub.2.alpha. isopropyl ester, containing a ring structure, substituted or unsubstituted, on the omega chain, selected from the group consisting of

20-phenyl-PGF.sub.2.alpha. isopropyl ester,

20-(4-phenylbutyl)-PGF.sub.2.alpha. isopropyl ester,

17-(2-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(3-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-methyl-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(4-trifluoromethyl phenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(4-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(2-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(4-fluorophenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

20(methylenephenyl)-PGF.sub.2.alpha. -isopropyl ester,

17-napthyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-cyclohexyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(4-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

17-(3-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,

15-cyclohexyl-16,17,18,19,20-pentanor-PGF.sub.2.alpha. isopropyl ester.

2. A therapeutic composition of claim 1, comprising 20-phenyl-PGF.sub.2.alpha. isopropyl ester.

3. A therapeutic composition of claim 1, comprising 20-(4-phenylbutyl)-PGF.sub.2.alpha. isopropyl ester.

4. A therapeutic composition of claim 1, comprising 17-(2-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

5. A therapeutic composition of claim 1, comprising 17-(3-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

6. A therapeutic composition of claim 1, comprising 17-methyl-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

7. A therapeutic composition of claim 1, comprising 17-(4-trifluoromethyl phenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

8. A therapeutic composition of claim 1, comprising 17-(4-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

9. A therapeutic composition of claim 1, comprising 17-(2-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

10. A therapeutic composition of claim 1, comprising 17-(4-fluorophenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

11. A therapeutic composition of claim 1, comprising 20(methylenephenyl)-PGF.sub.2.alpha. -isopropyl ester.

12. A therapeutic composition of claim 1, comprising 17-napthyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

13. A therapeutic composition of claim 1, comprising 17-cyclohexyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

14. A therapeutic composition of claim 1, comprising 17-(4-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

15. A therapeutic composition of claim 1, comprising 17-(3-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.

16. A therapeutic composition of claim 1, comprising 15-cyclohexy-16,17,18,19,20-pentanor-PGF.sub.2.alpha. isopropyl ester.

17. A method of treating ocular hypertension or glaucoma by topical application of the therapeutic composition of claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc